Intermittent EGFR-TKI therapy is associated with durable response in advanced EGFR-mutant NSCLC: a case report
Madam S, who diagnosed to have stage IV lung adenocarcinoma with exon 21 L858R point mutation (T3N2M1a) was admitted for massive pericardial effusion in April 2016. She was ECOG 4 on admission. Her ECOG improved to 1 after pericardial tapping and initiation of free sample erlotinib 100 mg daily. Rep...
Saved in:
Main Authors: | Tan, Sin Nee, Ibrahim, Aishah, Abdul Razak, Megat Razeem, Abdul Azih, Muhammad Naimmuddin, How, Soon Hin |
---|---|
Format: | Article |
Language: | English English |
Published: |
Faculty of Medicine and Health Sciences, University Putra Malaysia
2023
|
Subjects: | |
Online Access: | http://irep.iium.edu.my/108703/7/108703_Intermittent%20EGFR-TKI%20therapy%20is%20associated%20with%20durable%20response.pdf http://irep.iium.edu.my/108703/8/108703_Intermittent%20EGFR-TKI%20therapy%20is%20associated%20with%20durable%20response_Scopus.pdf http://irep.iium.edu.my/108703/ https://medic.upm.edu.my/jurnal_kami/volume_19_2023/mjmhs_vol19_no_2_march_2023-72022 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Outcomes of patients with EGFR-mutant
advanced NSCLC in a developing country in
Southeast Asia
by: How, Soon Hin, et al.
Published: (2022) -
Outcomes of patients with EGFR-mutant advanced NSCLC in a developing country in Southeast Asia
by: How, Soon Hin, et al.
Published: (2022) -
Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study
by: Ho, Gwo Fuang, et al.
Published: (2019) -
Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study
by: Chai, Chee Shee, et al.
Published: (2019) -
Identification of GPX4 as a therapeutic target for lung adenocarcinoma after EGFR-TKI resistance
by: Zhang, Chuanfen, et al.
Published: (2022)